Revista de Senologia y Patologia Mamaria最新文献

{"title":"VABe in B2 and B3 lesions: stopping surgery where it is no longer needed","authors":"Florentina Guzmán Aroca","doi":"10.1016/j.senol.2026.100777","DOIUrl":"10.1016/j.senol.2026.100777","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 2","pages":"Article 100777"},"PeriodicalIF":0.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147858151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating caspase-3 expression and activity in mammary tumor: prognostic significance and therapeutic implications","authors":"Fida Noor ,&nbsp;Hafeez Noor","doi":"10.1016/j.senol.2026.100780","DOIUrl":"10.1016/j.senol.2026.100780","url":null,"abstract":"<div><div>Caspase-3 is a leading executioner of apoptosis and a central intersection of intrinsic and extrinsic death pathways of cancer cells. Breast cancer (BC) remains the most commonly diagnosed malignancy in women worldwide and the leading cause of cancer-related death, with metastasis being the primary operator of death. Notably, upraised caspase-3 expression is associated with adverse clinical outcomes, including lymph node metastasis and distant repetition, challenging its traditional interpretation as a potent marker of apoptosis. In contrast, caspase-8, an initiator of extrinsic apoptotic pathways, has shown limited prognostic significance in breast cancer despite its clear role in other malignancies. Moreover, the interaction of apoptotic signaling with cell cycle machinery - particularly through cyclin-dependent kinase 2 (CDK2) - adds additional complexity, as CDK2 can directly phosphorylate and inactivate caspase-3, thereby inhibiting apoptosis while promoting proliferation and invasion. It has been proposed that end tumor cells undergoing caspase-3 stimulation can release pro-growth factors that promote the proliferation of surviving cancer cells, a phenomenon sometimes referred to as the “phoenix rise” pathway. This review critically synthesizes the actual knowledge of caspase-3 and caspase-8 in BC, explores their non-apoptotic functions in invasion and metastasis, integrates comparative insights from canine mammary tumor (CMT), and details the CDK2-caspase-3 mechanism as a novel mechanistic link between cell cycle dysregulation, apoptotic resistance, and metastatic progression that is important for biomarker improvement and targeted therapy.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 2","pages":"Article 100780"},"PeriodicalIF":0.2,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147858152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular imaging in breast cancer: A practical point of view","authors":"Ana María García-Vicente ,&nbsp;Catalina María Sampol-Bas ,&nbsp;José Ramón García-Garzón ,&nbsp;Monserrat Cortés-Romera","doi":"10.1016/j.senol.2026.100755","DOIUrl":"10.1016/j.senol.2026.100755","url":null,"abstract":"<div><div>Molecular imaging, defined by positron emission tomography/computed tomography (PET/CT) with ¹⁸F-Fluorodesoxiglucose [¹⁸F]FDG, plays a pivotal role in the clinical management of breast cancer (BS), providing essential information for accurate staging, early detection of recurrence and supporting the selection and monitoring of personalized treatment strategies. Magnetic resonance imaging (MRI), the most sensitive technique in BC detection, offers a potentially valuable support, as a partner of PET, in hybrid PET/MRI scans, especially in locoregional disease assessment or some distant metastases locations. In addition, <em>radiomics-</em>derived parameters and machine learning approaches can refine molecular stratification with insights into treatment and prognosis.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100755"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear medicine and breast cancer: A key discipline in diagnostic and therapeutic personalization","authors":"Sergi Vidal-Sicart","doi":"10.1016/j.senol.2026.100761","DOIUrl":"10.1016/j.senol.2026.100761","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100761"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-COVID-19 cardiorespiratory profile in breast cancer patients: a comparative analysis","authors":"Ani Paula Brasil ,&nbsp;Brenda Stephanie Fiuza ,&nbsp;Aedra Carla Bufalo Kawassaki ,&nbsp;Carlos Victor Pereira dos Santos ,&nbsp;Guilherme Cirino Rodrigues ,&nbsp;Larissa Luiza Bedin ,&nbsp;Rodrigo Kern ,&nbsp;Volmir Benedetti ,&nbsp;Daniel Rech ,&nbsp;Carolina Panis","doi":"10.1016/j.senol.2025.100725","DOIUrl":"10.1016/j.senol.2025.100725","url":null,"abstract":"<div><h3>Objective</h3><div>To perform a comparative analysis of the post-COVID-19 cardiorespiratory profile in women with breast cancer.</div></div><div><h3>Methods</h3><div>A mixed case–control study was conducted from January 2020 to June 2024 at the Francisco Beltrão Cancer Hospital in Paraná. Four groups of 14 participants, matched by age, were analyzed based on their history of COVID-19 and breast cancer. All participants underwent tests to assess respiratory muscle strength, cardiorespiratory functional capacity, and dyspnea. For women with breast cancer, additional data on the clinical-pathological profile of the disease were also collected.</div></div><div><h3>Results</h3><div>COVID-19 exacerbated the reduction in respiratory muscle strength already present in women with breast cancer and contributed to the occurrence and persistence of dyspnea, even 24 months post-infection. However, it did not significantly affect functional exercise capacity.</div></div><div><h3>Conclusion</h3><div>These findings emphasize the need for a multidisciplinary approach to conduct more comprehensive assessments, particularly in patients with breast cancer during the post-COVID phase.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100725"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nodular fasciitis of the breast","authors":"Rocío Ávila Figueroa ,&nbsp;Ángel Pareja López ,&nbsp;Juan Manuel Rodríguez Alonso","doi":"10.1016/j.senol.2026.100743","DOIUrl":"10.1016/j.senol.2026.100743","url":null,"abstract":"<div><div>Nodular Fasciitis in the breast is a rare pathology, categorized as a benign mesenchymal-origin breast tumor, with higher prevalence in middle-aged women. Its diagnosis is complex due to its low incidence and non-specific clinical presentation. However, although some authors suggest that microtrauma may be the origin, most patients do not report a history of trauma in the affected area. The pathology presents as a firm, painless, or slightly painful nodule that simulates breast cancer, typically located in the upper-outer quadrant (UOQ). The most common diagnostic tests are Mammography, which shows a dense and irregular nodule, and Ultrasound, which reveals a hypoechoic lesion with irregular margins. Excisional biopsy is the most commonly used procedure, with microscopic findings such as fibroblasts and frequent mitosis without atypia. A less invasive treatment is vacuum-assisted ultrasound-guided excision, although in some cases, a “wait and see” approach may be chosen due to the high rate of spontaneous resolution. Recurrences are exceptional, and the prognosis is generally favorable, although further studies are needed to draw definitive conclusions about its management and treatment. This article aims to summarize the currently available literature on this rare benign breast pathology, providing updated data—including immunohistochemical markers—to support clinicians in routine clinical practice.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100743"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147398109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimally invasive laser therapy for the small and large breast tumours: clinical applications and limitations","authors":"Deepak Kumar ,&nbsp;Rishabha Malviya ,&nbsp;Sathvik Belagodu Sridhar","doi":"10.1016/j.senol.2025.100724","DOIUrl":"10.1016/j.senol.2025.100724","url":null,"abstract":"<div><div>Breast cancer is a major cause of death globally, and traditional treatments like mastectomy and lumpectomy require extensive surgery, recovery times, and cosmetic issues. Minimally invasive laser treatment offers a potential alternative. This study assesses the clinical effectiveness, safety, and limits of Laser therapy for treating small and large breast cancers, comparing it with standard surgical techniques. Minimally invasive laser treatment uses thermal ablation to target tumours, with high success rates in ultrasound and MRI-guided procedures. Optical coherence tomography (OCT)-guided laser ablation improves accuracy, particularly for small breast tumours. However, problems like partial ablation of larger tumours and skin burns remain. MRI-based heat mapping improves therapy monitoring, and upcoming multimodal imaging and artificial intelligence integration promise better accuracy. This treatment also shows promise in palliative care, reducing tumour burden and improving patient lifecycle quality. Minimally invasive laser therapy is an appropriate and successful alternative to conventional breast cancer therapy, delivering superior cosmetic results and less morbidity.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100724"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phytoestrogen-mediated modulation of estrogen receptors: elucidating the binding interactions and pharmacokinetic profiles in breast cancer treatment","authors":"Dhilna Francis ,&nbsp;R.N. Binitha","doi":"10.1016/j.senol.2025.100731","DOIUrl":"10.1016/j.senol.2025.100731","url":null,"abstract":"<div><h3>Introduction</h3><div>Estrogen receptor (ER) signaling is central to the pathogenesis and therapeutic targeting of breast cancer. ER signaling is modulated differentially by its subtypes, with ER-alpha promoting cell growth and ER-beta acting as a suppressor. Estradiol is the dominant endogenous estrogen before menopause, whereas estrone predominates postmenopause, further complicating hormonal dynamics in breast tissue.</div></div><div><h3>Objective</h3><div>To investigate the binding affinities and selectivity of 15 phytoestrogen molecules to ER-alpha and ER-beta receptors in comparison to endogenous estrogens (estradiol and estrone) and to evaluate their druglikeness for oral absorption using Lipinski's Rule of Five.</div></div><div><h3>Methods</h3><div>Molecular docking analysis was performed to assess the binding interactions between the selected phytoestrogens, ER-alpha, ER-beta, estradiol, and estrone. Lipinski's Rule of Five was applied to determine the phytoestrogens' suitability for oral administration.</div></div><div><h3>Results</h3><div>Genistein, Daidzein, and Glycitein demonstrated strong and preferential binding to ER-beta compared to ER-alpha. The remaining phytoestrogens analyzed displayed greater affinity for ER-alpha. All phytoestrogens were evaluated for druglikeness, with the majority meeting Lipinski's Rule of Five criteria, suggesting favorable oral absorption potential.</div></div><div><h3>Conclusions</h3><div>The selective binding of Genistein, Daidzein, and Glycitein to ER-beta highlights their possible anti-tumor effects and positions them as promising candidates for further biological and pharmacological evaluation with respect to ER-beta-mediated breast cancer therapy. Distinct interactions of phytoestrogens with ER isoforms underscore the importance of receptor subtype targeting in breast cancer research and therapy development.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100731"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experimental animal models of chemically induced breast cancer: An update","authors":"Jayesh D. Kadam,&nbsp;Yogesh A. Kulkarni","doi":"10.1016/j.senol.2025.100730","DOIUrl":"10.1016/j.senol.2025.100730","url":null,"abstract":"<div><div>Breast cancer is the most commonly diagnosed and the second leading cause of death (cancer-related) among women globally, with metastasis significantly contributing to morbidity and mortality. This review explores various chemically induced animal models employed in breast cancer research, focusing on their mechanisms, challenges, and applications in understanding tumor biology and metastasis. This review also addresses the limitations and advantages of current models with respect to replicating human breast cancer heterogeneity, particularly in aggressive subtypes like triple-negative breast cancer. By comparing the molecular characteristics of human tumors with those of experimental models, this article emphasizes the need for diverse approaches to better mimic human disease and improve therapeutic outcomes. Ultimately, this comprehensive overview highlights the critical role of animal models in advancing breast cancer research and the ongoing efforts to refine these systems for more effective translational applications.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100730"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145981597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular profiles as predictors of locoregional recurrence-free survival in breast cancer radiotherapy","authors":"Gerardo Cuamani-Mitznahuatl ,&nbsp;Cindy Sharon Ortiz-Arce ,&nbsp;Julia A. Sáenz-Frias ,&nbsp;Dolores De la Mata ,&nbsp;Jorge Anselmo Vázquez-Delgado ,&nbsp;Alma D. Campos-Parra ,&nbsp;Catalina Tenorio-Téllez ,&nbsp;Miguel Ángel Souto-Del Bosque","doi":"10.1016/j.senol.2025.100720","DOIUrl":"10.1016/j.senol.2025.100720","url":null,"abstract":"<div><h3>Introduction</h3><div>Radiotherapy (RT) is a cornerstone of breast cancer (BC) treatment, hypofractionated radiotherapy (HypoF) emerging as a safe and effective fractionation. However, the role of molecular profiles (MP) in predicting the impact of different RT regimens on locoregional recurrence-free survival (LRFS) remains poorly understood. Personalized RT, tailored to tumor biology, could enhance outcomes by optimizing fractionation schemes for individual subtypes.</div></div><div><h3>Methods</h3><div>Retrospective cohort study included 290 breast cancer patients treated with adjuvant RT in 2016. Patients were classified by MP (luminal A, luminal B, HER2<!--> <!-->+, and triple-negative), and received either conventional (50 Gy/25 fractions) or hypofractionated (40.5 Gy/15 fractions) radiotherapy. Descriptive, univariate, and multivariate analyses were performed, and Kaplan–Meier survival curves with log-rank tests were used to assess LRFS.</div></div><div><h3>Results</h3><div>Of the 290 patients, most patients received conventional RT (51.7%), while 48.3% received hypofractionation. Luminal A showed the longest LRFS (68.2 months), but no significant difference was observed between subtypes (<em>p</em> = 0.058). The five-year LRFS was highest in luminal A patients (CF: 94.4%, HypoF: 98.5%), with no significant difference (<em>p</em> = 0.183). Notably, triple-negative patients had better LRFS with HypoF (100%) compared to CF (73.1%) (<em>p</em> = 0.017).</div></div><div><h3>Conclusion</h3><div>Luminal A subtypes exhibited higher LRFS regardless of RT type, while triple-negative BC patients achieved better outcomes with HypoF. Overall, higher LRFS were associated with BCS and HypoF treatments. These results highlight the importance of tailoring RT strategies to molecular subtypes to optimize outcomes. Further validation through larger studies is essential.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"39 1","pages":"Article 100720"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145957684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}